Evaluating the use of Uromune® autovaccine in recurrent urinary tract infections: a pilot unicenter retrospective study in Reus, Spain
Abstract Background Urinary tract infections (UTIs) are a significant global health issue, especially among women, with growing concerns related to antibiotic resistance and adverse effects. The Uromune®, a sublingual, heat-inactivated, polybacterial vaccine, represents a promising therapeutic alter...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-025-10524-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586005853503488 |
|---|---|
| author | Simona Iftimie Paula Ladero-Palacio Ana F. López-Azcona Laia Pujol-Galarza Antoni Pont-Salvadó Xavier Gabaldó-Barrios Jorge Joven Jordi Camps Antoni Castro Mercè Pascual-Queralt |
| author_facet | Simona Iftimie Paula Ladero-Palacio Ana F. López-Azcona Laia Pujol-Galarza Antoni Pont-Salvadó Xavier Gabaldó-Barrios Jorge Joven Jordi Camps Antoni Castro Mercè Pascual-Queralt |
| author_sort | Simona Iftimie |
| collection | DOAJ |
| description | Abstract Background Urinary tract infections (UTIs) are a significant global health issue, especially among women, with growing concerns related to antibiotic resistance and adverse effects. The Uromune®, a sublingual, heat-inactivated, polybacterial vaccine, represents a promising therapeutic alternative by enhancing immune responses against uropathogens. Methods This pilot retrospective study, conducted at Hospital Universitari de Sant Joan de Reus from January 2018 to August 2022, assessed the association between Uromune® administration and changes in recurrent UTIs. Patients received personalized autovaccines administered as two sublingual puffs daily for three months. Clinical, microbiological, and demographic data were analyzed to assess treatment outcomes and identify recurrence-associated factors. Results Forty-nine patients (mean age, 61 years, and 59.2% women) were included in the study. Uromune® treatment decreased UTI episodes from 3.73 ± 0.97 the year before to 0.98 ± 1.36 (p < 0.001) the year after its administration. The number of patients who suffered three or more episodes per year dropped from 43 (87.7%) before the intervention to 7 (14.3%) afterwards. The maximum effectiveness of the autovaccine was observed three months post-administration, with 44 patients not experiencing any UTI episodes. Regression analysis identified having had a urostomy, chronic kidney disease, and being immunosuppressed as predictors of recurrence. Conclusion Uromune® autovaccine was associated with a significant reduction in the frequency of recurrent UTIs and related hospitalizations, offering substantial relief to patients. These findings suggest that Uromune® may be a promising option for managing recurrent UTIs, though controlled studies are needed to confirm its efficacy compared to standard treatments. |
| format | Article |
| id | doaj-art-9e450e4ee3214d4abb0f2edc132c7949 |
| institution | Kabale University |
| issn | 1471-2334 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj-art-9e450e4ee3214d4abb0f2edc132c79492025-01-26T12:17:02ZengBMCBMC Infectious Diseases1471-23342025-01-0125111510.1186/s12879-025-10524-2Evaluating the use of Uromune® autovaccine in recurrent urinary tract infections: a pilot unicenter retrospective study in Reus, SpainSimona Iftimie0Paula Ladero-Palacio1Ana F. López-Azcona2Laia Pujol-Galarza3Antoni Pont-Salvadó4Xavier Gabaldó-Barrios5Jorge Joven6Jordi Camps7Antoni Castro8Mercè Pascual-Queralt9Research Group on Autoimmunity, Infection and Thrombosis (GRAIIT), Department of Internal Medicine, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i VirgiliResearch Group on Autoimmunity, Infection and Thrombosis (GRAIIT), Department of Internal Medicine, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i VirgiliResearch Group on Autoimmunity, Infection and Thrombosis (GRAIIT), Department of Internal Medicine, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i VirgiliDepartment of Urology, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i VirgiliDepartment of Urology, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i VirgiliDepartment of Clinical Laboratory, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i VirgiliUnitat de Recerca Biomèdica, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i VirgiliUnitat de Recerca Biomèdica, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i VirgiliResearch Group on Autoimmunity, Infection and Thrombosis (GRAIIT), Department of Internal Medicine, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i VirgiliDepartment of Urology, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i VirgiliAbstract Background Urinary tract infections (UTIs) are a significant global health issue, especially among women, with growing concerns related to antibiotic resistance and adverse effects. The Uromune®, a sublingual, heat-inactivated, polybacterial vaccine, represents a promising therapeutic alternative by enhancing immune responses against uropathogens. Methods This pilot retrospective study, conducted at Hospital Universitari de Sant Joan de Reus from January 2018 to August 2022, assessed the association between Uromune® administration and changes in recurrent UTIs. Patients received personalized autovaccines administered as two sublingual puffs daily for three months. Clinical, microbiological, and demographic data were analyzed to assess treatment outcomes and identify recurrence-associated factors. Results Forty-nine patients (mean age, 61 years, and 59.2% women) were included in the study. Uromune® treatment decreased UTI episodes from 3.73 ± 0.97 the year before to 0.98 ± 1.36 (p < 0.001) the year after its administration. The number of patients who suffered three or more episodes per year dropped from 43 (87.7%) before the intervention to 7 (14.3%) afterwards. The maximum effectiveness of the autovaccine was observed three months post-administration, with 44 patients not experiencing any UTI episodes. Regression analysis identified having had a urostomy, chronic kidney disease, and being immunosuppressed as predictors of recurrence. Conclusion Uromune® autovaccine was associated with a significant reduction in the frequency of recurrent UTIs and related hospitalizations, offering substantial relief to patients. These findings suggest that Uromune® may be a promising option for managing recurrent UTIs, though controlled studies are needed to confirm its efficacy compared to standard treatments.https://doi.org/10.1186/s12879-025-10524-2Antibiotic resistanceImmunotherapyRecurrent urinary tract infectionsSublingual bacterial vaccineUromune® vaccine |
| spellingShingle | Simona Iftimie Paula Ladero-Palacio Ana F. López-Azcona Laia Pujol-Galarza Antoni Pont-Salvadó Xavier Gabaldó-Barrios Jorge Joven Jordi Camps Antoni Castro Mercè Pascual-Queralt Evaluating the use of Uromune® autovaccine in recurrent urinary tract infections: a pilot unicenter retrospective study in Reus, Spain BMC Infectious Diseases Antibiotic resistance Immunotherapy Recurrent urinary tract infections Sublingual bacterial vaccine Uromune® vaccine |
| title | Evaluating the use of Uromune® autovaccine in recurrent urinary tract infections: a pilot unicenter retrospective study in Reus, Spain |
| title_full | Evaluating the use of Uromune® autovaccine in recurrent urinary tract infections: a pilot unicenter retrospective study in Reus, Spain |
| title_fullStr | Evaluating the use of Uromune® autovaccine in recurrent urinary tract infections: a pilot unicenter retrospective study in Reus, Spain |
| title_full_unstemmed | Evaluating the use of Uromune® autovaccine in recurrent urinary tract infections: a pilot unicenter retrospective study in Reus, Spain |
| title_short | Evaluating the use of Uromune® autovaccine in recurrent urinary tract infections: a pilot unicenter retrospective study in Reus, Spain |
| title_sort | evaluating the use of uromune r autovaccine in recurrent urinary tract infections a pilot unicenter retrospective study in reus spain |
| topic | Antibiotic resistance Immunotherapy Recurrent urinary tract infections Sublingual bacterial vaccine Uromune® vaccine |
| url | https://doi.org/10.1186/s12879-025-10524-2 |
| work_keys_str_mv | AT simonaiftimie evaluatingtheuseofuromuneautovaccineinrecurrenturinarytractinfectionsapilotunicenterretrospectivestudyinreusspain AT paulaladeropalacio evaluatingtheuseofuromuneautovaccineinrecurrenturinarytractinfectionsapilotunicenterretrospectivestudyinreusspain AT anaflopezazcona evaluatingtheuseofuromuneautovaccineinrecurrenturinarytractinfectionsapilotunicenterretrospectivestudyinreusspain AT laiapujolgalarza evaluatingtheuseofuromuneautovaccineinrecurrenturinarytractinfectionsapilotunicenterretrospectivestudyinreusspain AT antonipontsalvado evaluatingtheuseofuromuneautovaccineinrecurrenturinarytractinfectionsapilotunicenterretrospectivestudyinreusspain AT xaviergabaldobarrios evaluatingtheuseofuromuneautovaccineinrecurrenturinarytractinfectionsapilotunicenterretrospectivestudyinreusspain AT jorgejoven evaluatingtheuseofuromuneautovaccineinrecurrenturinarytractinfectionsapilotunicenterretrospectivestudyinreusspain AT jordicamps evaluatingtheuseofuromuneautovaccineinrecurrenturinarytractinfectionsapilotunicenterretrospectivestudyinreusspain AT antonicastro evaluatingtheuseofuromuneautovaccineinrecurrenturinarytractinfectionsapilotunicenterretrospectivestudyinreusspain AT mercepascualqueralt evaluatingtheuseofuromuneautovaccineinrecurrenturinarytractinfectionsapilotunicenterretrospectivestudyinreusspain |